GLAXF - Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts

2024-04-16 18:25:52 ET

Summary

• Lyell Immunopharma, Inc.'s stock price has risen over 20% YTD and over 45% in the past 12 months.
• The company focuses on T-cell therapies for solid tumors and has two clinical-stage assets.
• Lyell has upcoming data catalysts, with Phase 1 results expected in the first half of 2024 and the second half of this year.
• The two programs in question involve a CAR-T cell therapy targeting breast and lung cancer and a TIL therapy targeting melanoma, lung, and colorectal cancer.
• Lyell has funding to last until 2027 and a review of its approach to designing cell therapies gives me some optimism upcoming data readouts can be positive - there is substantial risk to this thesis; however, that must be acknowledged.

Investment Overview

Lyell Immunopharma, Inc.'s ( LYEL ) stock price has risen by >20% year to date and >45% across the past 12 months. The stock has been moderately volatile, reaching highs of >$3 in early March, and at the end of last week, before dropping this week back to $2.4 (at the time of writing).

Lyell IPO'd in June 2021, raising ~$425m via the issuance of 25m shares priced at $17 per share, so on a long-term basis, returns have been poor - but is the company positioned to embark on a longer term bull run?...

For further details see: